CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.18
3.25%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Fri: 08:00 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.16
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022085 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022085%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000137 %
Charges from full value of position ($-0.03)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000137%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange France
Commission on trade 0%

*Information provided by Capital.com

Genfit SA ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.08
Open* 3.15
1-Year Change* -22.22%
Day's Range* 3.09 - 3.22
52 wk Range 2.84-4.92
Average Volume (10 days) 191.51K
Average Volume (3 months) 5.34M
Market Cap 158.23M
P/E Ratio -100.00K
Shares Outstanding 49.84M
Revenue 29.75M
EPS -0.69
Dividend (Yield %) N/A
Beta 1.06
Next Earnings Date Apr 4, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 3.18 0.11 3.58% 3.07 3.23 3.07
Feb 29, 2024 3.08 -0.13 -4.05% 3.21 3.26 3.08
Feb 28, 2024 3.21 -0.12 -3.60% 3.33 3.33 3.19
Feb 27, 2024 3.36 0.13 4.02% 3.23 3.36 3.23
Feb 26, 2024 3.24 0.01 0.31% 3.23 3.30 3.22
Feb 23, 2024 3.28 -0.02 -0.61% 3.30 3.37 3.24
Feb 22, 2024 3.28 0.01 0.31% 3.27 3.40 3.22
Feb 21, 2024 3.22 -0.17 -5.01% 3.39 3.40 3.22
Feb 20, 2024 3.33 -0.08 -2.35% 3.41 3.48 3.33
Feb 19, 2024 3.40 -0.14 -3.95% 3.54 3.54 3.40
Feb 16, 2024 3.50 -0.01 -0.28% 3.51 3.59 3.48
Feb 15, 2024 3.45 -0.03 -0.86% 3.48 3.52 3.40
Feb 14, 2024 3.46 0.04 1.17% 3.42 3.50 3.40
Feb 13, 2024 3.42 -0.11 -3.12% 3.53 3.62 3.40
Feb 12, 2024 3.49 0.07 2.05% 3.42 3.75 3.41
Feb 9, 2024 3.40 0.05 1.49% 3.35 3.48 3.34
Feb 8, 2024 3.44 0.07 2.08% 3.37 3.48 3.37
Feb 7, 2024 3.39 -0.18 -5.04% 3.57 3.60 3.39
Feb 6, 2024 3.54 0.05 1.43% 3.49 3.59 3.47
Feb 5, 2024 3.44 -0.05 -1.43% 3.49 3.56 3.44

Genfit SA Events

Time (UTC) Country Event
Thursday, April 4, 2024

Time (UTC)

14:00

Country

FR

Event

Full Year 2023 Genfit SA Earnings Release
Full Year 2023 Genfit SA Earnings Release

Forecast

-

Previous

-
Tuesday, May 14, 2024

Time (UTC)

20:10

Country

FR

Event

Q1 2024 Genfit SA Corporate Sales Release
Q1 2024 Genfit SA Corporate Sales Release

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

10:59

Country

FR

Event

Genfit SA Annual Shareholders Meeting
Genfit SA Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 26.566 85.579 7.758 40.961 7.494
Revenue 26.566 85.579 7.758 40.961 7.494
Cost of Revenue, Total 2.124 1.471 2.078 2.194 1.854
Gross Profit 24.442 84.108 5.68 38.767 5.64
Total Operating Expense 53.855 18.185 90.655 98.793 76.978
Selling/General/Admin. Expenses, Total 7.829 8.989 18.154 21.29 4.197
Research & Development 27.437 27.002 50.771 53.249 57.091
Depreciation / Amortization 1.48 2.801 1.57 5.25 1.707
Unusual Expense (Income) -0.016 -35.145 5.388 -0.019 -0.002
Other Operating Expenses, Total 15.001 13.067 12.694 16.829 12.131
Operating Income -27.289 67.394 -82.897 -57.832 -69.484
Interest Income (Expense), Net Non-Operating 2.857 2.032 -18.86 -8.197 -10.8
Other, Net 0.596 0.048 0.108 0.308 0.409
Net Income Before Taxes -23.836 69.474 -101.649 -65.721 -79.875
Net Income After Taxes -23.72 67.259 -101.221 -65.145 -79.521
Minority Interest 0 0 0 0
Net Income Before Extra. Items -23.72 67.259 -101.221 -65.145 -79.521
Net Income -23.72 67.259 -101.221 -65.145 -79.521
Income Available to Common Excl. Extra. Items -23.719 67.259 -101.221 -65.144 -79.521
Income Available to Common Incl. Extra. Items -23.719 67.259 -101.221 -65.144 -79.521
Diluted Net Income -23.719 67.259 -101.221 -65.144 -79.521
Diluted Weighted Average Shares 49.6739 55.6136 38.8586 36.988 31.1672
Diluted EPS Excluding Extraordinary Items -0.47749 1.2094 -2.60485 -1.76122 -2.55143
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -0.4777 0.5976 -2.51473 -1.76155 -2.55147
Total Adjustments to Net Income 0.001 0.001
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total revenue 15.374 14.378 12.188 80.059 3.428
Revenue 15.374 14.378 12.188 80.059 3.428
Cost of Revenue, Total 1.202 0.939 1.185 0.756 0.715
Gross Profit 14.172 13.439 11.003 79.303 2.713
Total Operating Expense 34.673 27.323 26.532 20.784 -2.599
Selling/General/Admin. Expenses, Total 4.529 4.104 3.725 4.821 4.168
Research & Development 20.667 14.01 13.427 7.13 19.872
Depreciation / Amortization 0.994 0.619 0.963 2.525 0.276
Unusual Expense (Income) -0.053 -0.017 0.001 0.092 -35.237
Other Operating Expenses, Total 7.334 7.668 7.231 5.46 7.607
Operating Income -19.299 -12.945 -14.344 59.275 6.027
Interest Income (Expense), Net Non-Operating -2.468 -0.999 3.857 1.893 0.139
Other, Net 1.327 0.467 0.128 0.051 -0.003
Net Income Before Taxes -20.44 -13.477 -10.359 61.219 6.163
Net Income After Taxes -20.854 -13.321 -10.399 56.109 9.058
Net Income Before Extra. Items -20.854 -13.321 -10.399 56.109 9.058
Net Income -20.854 -13.321 -10.399 56.109 9.058
Income Available to Common Excl. Extra. Items -20.854 -13.32 -10.399 56.109 9.058
Income Available to Common Incl. Extra. Items -20.854 -13.32 -10.399 56.109 9.058
Diluted Net Income -20.854 -13.32 -10.399 56.109 9.058
Diluted Weighted Average Shares 49.7019 49.6791 49.6687 67.5406 43.6867
Diluted EPS Excluding Extraordinary Items -0.41958 -0.26812 -0.20937 0.83075 0.20734
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -0.42028 -0.26834 -0.20935 0.83199 -0.31694
Minority Interest 0
Total Adjustments to Net Income 0.001
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 158.459 268.097 184.717 290.753 218.116
Cash and Short Term Investments 140.551 258.756 171.029 276.748 207.24
Cash 16.91 189.711 4.995 13.601 5.718
Cash & Equivalents 119.091 69.045 166.034 263.147 201.522
Short Term Investments 4.55 0
Total Receivables, Net 15.906 7.236 11.919 12.033 8.794
Accounts Receivable - Trade, Net 3.188 0.055 0.793 0.206 0.026
Total Inventory 0.004 0.004 0.004 0.004 0.004
Prepaid Expenses 1.998 2.101 1.765 1.968 2.078
Total Assets 215.54 281.72 198.614 309.853 229.478
Property/Plant/Equipment, Total - Net 8.21 9.015 11.648 16.453 7.764
Property/Plant/Equipment, Total - Gross 20.794 20.018 24.91 27.238 15.774
Accumulated Depreciation, Total -12.584 -11.003 -13.262 -10.785 -8.01
Intangibles, Net 43.957 0.174 0.791 0.92 0.796
Long Term Investments 4.914 4.431 1.458 1.727 1.313
Other Long Term Assets, Total 0 0 0 0 0
Total Current Liabilities 39.37 62.837 31.067 43.657 39.248
Accounts Payable 8.613 12.304 20.337 32.753 32.649
Accrued Expenses 4.852 4.103 4.478 3.599 2.969
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 5.066 2.171 4.34 4.529 3.151
Other Current Liabilities, Total 20.839 44.259 1.912 2.776 0.479
Total Liabilities 121.012 162.623 214.776 225.788 208.539
Total Long Term Debt 70.195 72.047 181.343 179.081 163.202
Long Term Debt 64.668 66.067 173.297 168.912 161.821
Capital Lease Obligations 5.527 5.98 8.046 10.169 1.381
Other Liabilities, Total 10.937 27.137 1.599 1.857 4.316
Total Equity 94.528 119.097 -16.162 84.065 20.939
Common Stock 12.459 12.454 9.722 9.715 7.796
Additional Paid-In Capital 444.683 444.438 379.057 377.821 251.554
Retained Earnings (Accumulated Deficit) -360.291 -336.831 -404.039 -303.007 -237.688
Treasury Stock - Common -0.978 -0.986 -0.811 -0.477 -0.73
Other Equity, Total -1.345 0.022 -0.091 0.013 0.007
Total Liabilities & Shareholders’ Equity 215.54 281.72 198.614 309.853 229.478
Total Common Shares Outstanding 49.835 49.8155 38.8586 38.8586 31.1839
Other Current Assets, Total
Note Receivable - Long Term 0 0.003 0 0 1.489
Deferred Income Tax 0.51 0.602 0.767 1.193 1.773
Minority Interest 0 0 0 0
Jun 2023 Dec 2022 Jun 2022 Dec 2021 Jun 2021
Total Current Assets 134.592 158.459 223.53 268.097 121.283
Cash and Short Term Investments 111.826 140.551 209.115 258.756 104.379
Cash 98.042 16.91 53.923 189.711 15.207
Cash & Equivalents 13.784 119.091 155.192 69.045 89.172
Total Receivables, Net 20.184 15.906 11.428 7.236 13.842
Accounts Receivable - Trade, Net 2.787 3.188 0.743 0.055 0.556
Total Inventory 0.004 0.004 0.004 0.004 0.004
Prepaid Expenses 2.578 1.998 2.982 2.101 3.058
Total Assets 193.905 215.54 237.049 281.72 133.712
Property/Plant/Equipment, Total - Net 8.144 8.21 8.554 9.015 10.328
Property/Plant/Equipment, Total - Gross 20.794 20.393 20.018 21.992
Accumulated Depreciation, Total -12.584 -11.839 -11.003 -11.664
Intangibles, Net 46.182 43.957 0.149 0.174 0.704
Long Term Investments 4.986 4.914 4.817 4.431 1.398
Other Long Term Assets, Total 0.001 0 -0.001 0 -0.001
Total Current Liabilities 45.66 39.37 35.288 62.837 30.964
Accounts Payable 15.883 8.614 10.23 12.304 23
Accrued Expenses 3.545 4.852 3.125 4.103 3.943
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 7.741 5.066 2.212 2.171 2.873
Other Current Liabilities, Total 18.491 20.838 19.721 44.259 1.148
Total Liabilities 119.385 121.012 127.883 162.623 101.146
Total Long Term Debt 67.674 70.195 72.499 72.047 64.828
Long Term Debt 62.649 64.668 66.721 66.067 58.065
Capital Lease Obligations 5.025 5.527 5.778 5.98 6.763
Deferred Income Tax 0.491 0.51 0.647 0.602 0.608
Minority Interest 0 0 0
Other Liabilities, Total 5.56 10.937 19.449 27.137 4.746
Total Equity 74.52 94.528 109.166 119.097 32.566
Common Stock 12.459 12.459 12.454 12.454 11.444
Additional Paid-In Capital 444.957 444.683 444.586 444.438 416.965
Retained Earnings (Accumulated Deficit) -380.872 -360.291 -347.005 -336.831 -394.937
Treasury Stock - Common -0.884 -0.978 -1.05 -0.986 -0.854
Other Equity, Total -1.14 -1.345 0.181 0.022 -0.052
Total Liabilities & Shareholders’ Equity 193.905 215.54 237.049 281.72 133.712
Total Common Shares Outstanding 49.835 49.835 49.8155 49.8155 45.7752
Note Receivable - Long Term 0 0 0.003
Other Current Assets, Total 0.001
Short Term Investments 0 4.55
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -23.719 67.259 -101.221 -65.144 -79.521
Cash From Operating Activities -72.638 99.915 -96.371 -47.679 -56.08
Cash From Operating Activities 1.832 2.742 3.559 3.263 1.819
Non-Cash Items 4.186 -29.766 12.42 14.558 11.194
Cash Taxes Paid 0.145 0 0 -0.093
Changes in Working Capital -54.937 59.68 -11.129 -0.356 10.428
Cash From Investing Activities -46.266 -3.377 -0.966 0.327 -3.986
Capital Expenditures -0.537 -0.9 -2.03 -2.938
Other Investing Cash Flow Items, Total -46.266 -2.84 -0.066 2.357 -1.048
Cash From Financing Activities -3.786 -8.916 -8.256 116.851 -6.514
Financing Cash Flow Items -2.043 -1.835 -6.32 -7.794 -6.351
Issuance (Retirement) of Stock, Net 0.005 27.972 0.007 126.529 0.037
Issuance (Retirement) of Debt, Net -1.748 -35.053 -1.943 -1.884 -0.2
Net Change in Cash -122.756 87.727 -105.719 69.499 -66.58
Foreign Exchange Effects -0.066 0.105 -0.126
Dec 2022 Jun 2022 Dec 2021 Jun 2021
Net income/Starting Line -23.719 -10.399 67.259 9.058
Cash From Operating Activities -72.638 -47.499 99.915 -27.81
Cash From Operating Activities 1.832 0.944 2.742 1.511
Non-Cash Items 4.186 2.267 -29.766 -36.688
Cash Taxes Paid 0.145 0 -0.006
Changes in Working Capital -54.937 -40.311 59.68 -1.691
Cash From Investing Activities -46.266 -0.199 -3.377 0.215
Capital Expenditures -0.537 -0.021
Other Investing Cash Flow Items, Total -46.266 -0.199 -2.84 0.236
Cash From Financing Activities -3.786 -1.943 -8.916 -38.966
Financing Cash Flow Items -2.043 -1.04 -1.835 -0.834
Issuance (Retirement) of Stock, Net 0.005 0 27.972 0
Issuance (Retirement) of Debt, Net -1.748 -0.903 -35.053 -38.132
Foreign Exchange Effects -0.066 0 0.105 -0.088
Net Change in Cash -122.756 -49.641 87.727 -66.649
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Ipsen Pharma SAS Corporation 7.9969 3985239 0 2023-05-04 LOW
Tang Capital Management, LLC Hedge Fund 4.917 2450404 1076667 2023-07-06 MED
Biotech Avenir SAS Holding Company 3.7897 1888618 0 2023-05-04 LOW
Université Lille 2 Corporation 1.3068 651250 0 2023-05-04
Sunny Asset Management Investment Advisor 0.2207 110000 0 2023-09-30 MED
CPR Asset Management Investment Advisor 0.2189 109111 0 2023-08-31 MED
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.0892 44474 0 2023-08-31 LOW
Mandarine Gestion Investment Advisor 0.082 40885 -9115 2023-04-30 LOW
Mouney (Jean-François) Individual Investor 0.0734 36594 0 2023-05-04 LOW
Clay Asset Management SAS Investment Advisor 0.0602 30000 30000 2023-06-30 LOW
Meeschaert Amilton Asset Management Investment Advisor 0.0492 24500 24500 2023-06-30 MED
Syquant Capital S.A.S Investment Advisor 0.0478 23812 -113906 2022-06-30 MED
Baillie Gifford & Co. Investment Advisor 0.0465 23168 -24083 2023-07-31 LOW
Prigent (Pascal) Individual Investor 0.0416 20708 20708 2023-05-04 HIGH
American Century Investment Management, Inc. Investment Advisor/Hedge Fund 0.0411 20500 256 2023-09-30 LOW
UNIQA Towarzystwo Funduszy Inwestycyjnych S. A Investment Advisor 0.0249 12400 12400 2022-12-31 MED
Dimensional Fund Advisors, Ltd. Investment Advisor 0.0231 11487 0 2023-09-30 LOW
Lannoo (Laurent) Individual Investor 0.0195 9736 9736 2023-04-01
Hum (Dean W) Individual Investor 0.0165 8204 8204 2023-04-01
Avantis Investors Investment Advisor 0.0116 5760 -22748 2023-09-30 MED

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Genfit Company profile

About Genfit SA

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Financial summary

BRIEF: For the six months ended 30 June 2021, Genfit SA revenues decreased 42% to EUR3.4M. Net income totaled EUR9.1M vs. loss of EUR53M. Revenues reflect Public Financing of research expenditure decrease of 38% to EUR3.2M, Other Operating Income decrease of 66% to EUR174K, Revenue decrease of 91% to EUR11K. Net Income reflects R&D Subcontractors decrease of 38% to EUR15M (expense).

Equity composition

01/2014, Rights Issue, 1 new share for every 33 shares held @ EUR6.98 (Factor: 1.00937).10/2016, Rights Issue, 1 new share for every 9 shares held @ EUR14.3 (Factor: 1.09242).

Industry: Biotechnology & Medical Research (NEC)

Parc Eurasanté 885 avenue Eugène Avinée
LOOS
HAUTS-DE-FRANCE 59120
FR

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

BTC/USD

61,959.35 Price
-0.970% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.64 Price
+6.540% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

79.49 Price
+1.850% 1D Chg, %
Long position overnight fee 0.0266%
Short position overnight fee -0.0485%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

18,286.90 Price
+1.410% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading